ArticleScientific reports2025
GTE score on evaluating the degree of neurological impairment in anti-NMDA receptor encephalitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A pediatric case of anti-GABAFrontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study mainly analyzed the EEG changes and the development of neurological impairment at different stages of the disease, and explored the clinical role of the Grand Total EEG score (GTE score) in evaluating the degree of neurological impairment function damage in anti-NMDA receptor encephalitis. The GTE scores of patients with anti-NMDA receptor encephalitis at different disease stages and the diagnostic validity of the GTE scores for evaluating the degree of neurological impairment were analyzed. 153 EEG cases were included in this study, with a course of 2 to 960 days. The abnormal EEG rates were 92% in the acute phase, 83% in the recovery phase, 76% in the short-term prognosis phase, and 30% in the long-term prognosis phase. The GTE score: acute phase=(5, 0-15); recovery phase=(2, 0-14); short-term prognosis phase= (2, 0-9); long-term prognosis phase = (0, 0-6). When the total GTE score is 5.5, the patient was more likely to have moderate to severe neurological impairment (mRS = 4), with sensitivity and specificity > 0.9. When the total GTE score was 7.5, the patient was more likely to have severe neurological impairment (mRS = 5), with sensitivity and specificity > 0.9. GTE score has a high diagnostic efficacy for the rating of neurological impairment. The total GTE score was superior to the assessment of neurological damage degree solely from background activity frequency or diffuse slow wave activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.